'Digoxin conundrum - Time for validation?'
- PMID: 33865529
- PMCID: PMC8065360
- DOI: 10.1016/j.ihj.2021.01.019
'Digoxin conundrum - Time for validation?'
Abstract
Despite no incontrovertible data, Digoxin use has been demonised. As a consequence, a lot of patients, stable on Digoxin, have been taken off it and offered alternative drugs. However, there is some light at the end of the tunnel for Digoxin, with the reporting of RATE-AF Trial at the recent European Society of Cardiology Congress. Compared to Bisoprolol, Digoxin use was associated with statistically significantly greater improvements in symptomatology and NT ProBNP levels making Digoxin a first line drug for rate control in permanent AF.
Keywords: Atrial fibrillation; Digoxin; Heart failure.
Copyright © 2021 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
References
-
- Turakhia M.P. Digoxin in atrial fibrillation? Leave it out of the medicine cabinet. J Am Coll Cardiol. 2018;71(10):1075–1077. - PubMed
-
- Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–533. - PubMed
-
- John M. vol. 30. 2020. (Mandrola. Digoxin Stuns in RATE-AF Trial - Medscape - Aug).
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
